ChemicalBook >> CAS DataBase List >>Actinomycin D

Actinomycin D

CAS No.
50-76-0
Chemical Name:
Actinomycin D
Synonyms
ad;DACTINOMYCIN;cosmegen;CACTINOMYCIN;actd;acto-d;nsc3053;AD(VAN);CS-2273;Cosmogen
CBNumber:
CB8853701
Molecular Formula:
C62H86N12O16
Molecular Weight:
1255.42
MDL Number:
MFCD00005033
MOL File:
50-76-0.mol
Last updated:2023-09-04 17:31:24

Actinomycin D Properties

Melting point 251-253 °C
Boiling point 848°C (rough estimate)
Density 1.0757 (rough estimate)
refractive index 1.5700 (estimate)
Flash point 87℃
storage temp. 2-8°C
solubility ethanol, DMSO: Stable in aqueous solutions at 2-8 °C.soluble
pka 8.94±0.70(Predicted)
form powder
color red, powder
optical activity [α]/D alpha: 28/D (Rotation: -315 degrees (c=0.25% in methanol))
Water Solubility SOLUBLE
Merck 13,2828
BRN 605235
Stability Stable, but light sensitive, especially in dilute solution. Incompatible with strong acids, strong bases, strong oxidizing agents. Combustible.
CAS DataBase Reference 50-76-0(CAS DataBase Reference)
EWG's Food Scores 4
NCI Dictionary of Cancer Terms actinomycin D; Cosmegen; dactinomycin
FDA UNII 1CC1JFE158
NCI Drug Dictionary Cosmegen
ATC code L01DA01
Proposition 65 List Actinomycin D
IARC 3 (Vol. 10, Sup 7) 1987
EPA Substance Registry System Actinomycin D (50-76-0)

Pharmacokinetic data

Protein binding 5%
Volume of distribution >12.1(L/kg)
Biological half-life 36 / -

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictogramsGHS hazard pictograms
GHS06,GHS08
Signal word  Danger
Hazard statements  H300-H350-H360FD
Precautionary statements  P201-P202-P264-P270-P280-P301+P310
Hazard Codes  T+
Risk Statements  28-61-40-45-26/27/28
Safety Statements  53-36/37/39-45-1-36/37-28-22
RIDADR  UN 3462 6.1/PG 2
WGK Germany  3
RTECS  AU1575000
8-10-21
HazardClass  6.1(a)
PackingGroup  II
HS Code  29419000
Toxicity LD50 oral in rat: 7200ug/kg
NFPA 704
0
4 0

Actinomycin D price More Price(55)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 114666 Actinomycin D 50-76-0 1set $260 2021-12-16 Buy
Alfa Aesar J67160 Actinomycin D, 1 mg/ml in DMSO, sterile-filtered 50-76-0 1ml $203 2024-03-01 Buy
Alfa Aesar J60148 Actinomycin D 50-76-0 5mg $129 2024-03-01 Buy
Cayman Chemical 11421 Actinomycin D ≥95% 50-76-0 5mg $67 2024-03-01 Buy
Cayman Chemical 11421 Actinomycin D ≥95% 50-76-0 10mg $120 2024-03-01 Buy
Product number Packaging Price Buy
114666 1set $260 Buy
J67160 1ml $203 Buy
J60148 5mg $129 Buy
11421 5mg $67 Buy
11421 10mg $120 Buy

Actinomycin D Chemical Properties,Uses,Production

Description

Actinomycin D (50-76-0) is a cyclopeptide antibiotic and intercalating transcription inhibitor with anti-neoplastic activity. Potent inhibitor of RNA polymerase.1?Induces apoptosis in a variety of cancer cell lines2,3via the intrinsic pathway4.? Upregulates proapoptotic PUMA and downregulates Bcl-2 mRNA in peripheral blood lymphocytes.5

Chemical Properties

red crystalline powder

Chemical Properties

Actinomycin D is a combustible, bright red crystalline solid.

Originator

Cosmegen,Merck Sharp and Dohme,US,1965

Uses

An antineoplastic antibiotic that inhibits cell proliferation by forming a stable complex with DNA and blocking the movement of RNA polymerase which interferes with DNA-dependent RNA synthesis. Induces apoptosis. Potent antitumor agent.

Uses

Antibiotic substance belonging to the actinomycin complex, produced by several Streptomyces spp. Antineoplastic

Uses

antineoplastic, intercalating agent

Uses

Actinomycin D is the most studied member of a family of unique bicyclic depsipeptides produced by several Streptomyces species. The depsipeptides are linked by a heterocyclic benzoxazone "anchor" that gives the metabolites a highly distinctive red/orange colour. Actinomycin D exhibits potent antibiotic and antitumour activity via DNA intercalation leading to the inhibition of nucleic acid synthesis. Tumour cell death has been demonstrated to occur by apoptosis.

Definition

ChEBI: Actinomycin D is an actinomycin. It has a role as a mutagen.

Indications

Dactinomycin (actinomycin D, Cosmegen) is one of a family of chromopeptides produced by Streptomyces. It is known to bind noncovalently to double-strand DNA by partial intercalation, inhibiting DNA-directed RNA synthesis. The drug is most toxic to proliferating cells, but it is not specific for any one phase of the cell cycle. Resistance to dactinomycin is caused by decreased ability of tumor cells to take up and retain the drug, and it is associated with cross-resistance to vinca alkaloids, the anthracyclines, and certain other agents (multidrug resistance).

Manufacturing Process

An incubated culture of Actinomyces antibioticus was prepared using a medium consisting of 1% tryptone-peptone, 0.5% starch, 0.2% K2HPO4, 0.2% NaCl and 0.25% agar in distilled water, grown at a temperature of approximately 25° to 35°C, the incubation being complete after 6 to 10 days. 50 liters of this incubated culture are extracted approximately six times with ether, using 20 liters of ether for each extraction.
The final extract is faintly pale yellow in color, whereas the previous extracts are orange. The combined ether extracts are concentrated to dryness and about 3 grams of a reddish-brown residue is obtained. The residue is stirred with approximately 400 cc of petroleum ether for two to three hours, the solvent decanted and the residue treated again with approximately 400 cc of petroleum ether. A pale yellow oil constituting crude actinomycin B is recovered by evaporation from the petroleum ether.
The dark petroleum ether insoluble residue is dissolved in 1 liter of benzene with gentle heating. Usually a small amount of black amorphous material remains undissolved and is filtered off. The benzene solution is permitted to drop through a chromatographic tower (60 x 5 cm) packed with aluminum oxide (according to Brockman). The pigment is readily adsorbed. The column is washed with about 1 liter of benzene during which operation very little migration of the color bands occurs.
The column is then washed with benzene-acetone solution (15:85) whereby a chromatogram develops. By continued washing, light yellow colored pigments pass out of the column. When the main band (orange-red) reaches the lower end of the column, a solution of 30:70 acetone-benzene is passed through the column. The latter solvent elutes the pigment and when the eluate is very pale in color, washing is discontinued.
The eluate is concentrated to dryness under reduced pressure, taken up in 25 cc of hot acetone, filtered, and diluted with ether. The pigment which crystallizes as red-brick colored platelets is essentially pure but may be recrystallized if desired from hot ethyl acetate. An analysis of the product showed C = 59.01; H = 6.81; N = 13.38.

brand name

Cosmegen (Ovation).

Therapeutic Function

Cancer chemotherapy

General Description

Bright red rhomboid prisms or red powder.

General Description

Dactinomycin is available in vials containing 0.5 mg of drugfor reconstitution in sterile water for IV administration Thisantibiotic is most effective in the treatment of rhabdomyosarcomaand Wilms tumor in children as well as in the treatmentof choriocarcinoma, Ewing sarcoma, Kaposi sarcoma, andtesticular carcinoma. The pharmacokinetics of dactinomycinhas not been well characterized, but it appears to concentratein nucleated blood cells. The agent is 5% to 15% plasmaprotein bound and is excreted mostly unchanged in urineand bile. Other metabolites have not been characterized.The terminal elimination half-life is 30 to 40 hours.Myelosuppression is dose limiting with both leucopenia andthrombocytopenia being the most likely presentation. Nauseaand vomiting occur shortly (2 hours) after treatment and maybe severe. Mucositis and diarrhea also result from irritation ofthe GI tract. Hair loss is commonly associated with the agentas is hyperpigmentation of the skin and erythema.

Air & Water Reactions

Water soluble.

Reactivity Profile

Actinomycin D can react with strong oxidizing agents, strong acids and strong bases.

Fire Hazard

Flash point data for Actinomycin D are not available. Actinomycin D is probably combustible.

Biological Activity

Anti-neoplastic antibiotic. Inhibits RNA polymerase and is a potent inducer of apoptosis.

Mechanism of action

Dactinomycin is cleared rapidly from plasma, does not enter the brain, is not appreciably metabolized or protein bound, and is gradually excreted in both bile and urine.Virtually no drug is detected in CSF.

Clinical Use

Dactinomycin is used in curative combined treatment of Wilms’ tumor, Ewing’s sarcoma, rhabdomyosarcoma, and gestational choriocarcinoma. It is active in testicular tumors, lymphomas, melanomas, and sarcomas, although its use in most of these malignancies has been supplanted by other agents.

Side effects

The major side effects of dactinomycin are severe nausea, vomiting, and myelosuppression. Mucositis, diarrhea, alopecia, and radiation recall reactions may occur. The drug is immunosuppressive and carcinogenic.

Potential Exposure

An antibiotic product from streptomyces, used as anticancer and veterinary drug

Veterinary Drugs and Treatments

Dactinomycin has been used as adjunctive treatment of lymphoreticular neoplasms, bone and soft tissue sarcomas, and carcinomas in small animals. It appears to have low efficacy against most carcinomas and sarcomas. It is being investigated as a part of protocols for rescue therapy for canine lymphomas.

Drug interactions

Potentially hazardous interactions with other drugs
Antipsychotics: increased risk of agranulocytosis with clozapine - avoid.
Cytotoxics: increased risk of hepatotoxicity with vincristine.
Vaccines: risk of generalised infections with live vaccines - avoid.

Metabolism

Intravenous doses of dactinomycin are rapidly distributed with high concentrations in bone marrow and nucleated cells. It undergoes only minimal metabolism and is slowly excreted in urine and bile. 15% is eliminated by hepatic metabolism. Approximately 30% of the dose was recovered in the urine and faeces in 1 week.

storage

+4°C

Shipping

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required.

Purification Methods

It crystallises as bright red rhombic crystals from absolute EtOH or from MeOH/EtOH (1:3). It will also crystallise from EtOAc/cyclohexane (m 246-247o dec), CHCl3/pet ether ( m 245-246o dec), and EtOAc/MeOH/*C6H6 (m 241-243o dec). Its solubility in MeCN is 1mg/mL. [] D varies from -296o to -327o (c 0.2, MeOH). max (MeOH) 445, 240nm (log  4.43, 4.49), max (MeOH, 10N HCl, 1:1) 477nm (log  4.21) and max (MeOH, 0.1N NaOH) 458, 344, 285 (log  3.05, 4.28, 4.13). It is HIGHLY TOXIC, light sensitive and anti-neoplastic. [Bullock & Johnson, J Chem Soc 3280 1957, Beilstein 27 III/IV 9642.]

Incompatibilities

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides.

References

1) Wagner?et al.(2013)?RNA Polymerase II acts as an RNA-dependent RNA polymerase to extend and destabilize a non-coding RNA ; EMBO J.?32?781 2) J. Kleeff?et al.?(2000)?Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells; Int. J. Cancer,?86?399 3) Kasim?et al.?(2013)?Live fluorescence and transmission-through-dye microscopic study of actinomycin D-induced apoptosis and apoptotic volume decrease?; Apoptosis,18?521 4) Liu?et al.?(2016)?Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis; Proc. Natl. Acad. Sci. USA,?113?10666 5) Kalousec?et al.?(2007)?Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes; Anticancer Drugs,?18?763 6) Matsuzaka?et al. (2016)?Characterization and functional analysis of extracellular vesicles and muscle-abundant miRNA in C2C12 myocytes and Mdx mice; PLoS One11(12)?e0167811 [Focus Biomolecules Citation]

2478-48-0
50-76-0
Synthesis of Actinomycin D from L-Valine, N-methyl-N-[N-methyl-N-[1-[N-[N-[4-methyl-2-nitro-3-(phenylmethoxy)benzoyl]-L-threonyl]-D-valyl]-L-prolyl]glycyl]-, ξ-lactone (9CI)

Actinomycin D Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 274)Suppliers
Supplier Tel Email Country ProdList Advantage
CONIER CHEM AND PHARMA LIMITED
+8618523575427 sales@conier.com China 47465 58
Hebei Mojin Biotechnology Co., Ltd
+8613288715578 sales@hbmojin.com China 12452 58
Shaanxi Haibo Biotechnology Co., Ltd
+86-02963020060 +86-18629295024 hibo06@xaltbio.com China 1000 58
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479 sales@fine-chemtech.com CHINA 885 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32480 60
career henan chemical co
+86-0371-86658258 sales@coreychem.com China 29914 58
SHANDONG ZHI SHANG CHEMICAL CO.LTD
+86 18953170293 sales@sdzschem.com China 2931 58
Biochempartner
0086-13720134139 candy@biochempartner.com CHINA 967 58
Hebei Guanlang Biotechnology Co., Ltd.
+86-19930503282 alice@crovellbio.com China 8823 58
Xiamen AmoyChem Co., Ltd
+86-592-6051114 +8618959220845 sales@amoychem.com China 6387 58

View Lastest Price from Actinomycin D manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Actinomycin D pictures 2023-11-08 Actinomycin D
50-76-0
US $0.00 / kg 1kg 99% 2000ton Shaanxi Haibo Biotechnology Co., Ltd
Actinomycin D pictures 2023-07-04 Actinomycin D
50-76-0
US $0.00 / KG 1KG 99% 50000KG/month Hebei Mojin Biotechnology Co., Ltd
Actinomycin D pictures 2022-08-31 Actinomycin D
50-76-0
US $1200.00-850.00 / g 10g 99% 25kg/ month Wuhan Qiami Technology Co., Ltd
  • Actinomycin D pictures
  • Actinomycin D
    50-76-0
  • US $0.00 / kg
  • 99%
  • Shaanxi Haibo Biotechnology Co., Ltd
  • Actinomycin D pictures
  • Actinomycin D
    50-76-0
  • US $0.00 / KG
  • 99%
  • Hebei Mojin Biotechnology Co., Ltd
  • Actinomycin D pictures
  • Actinomycin D
    50-76-0
  • US $1200.00-850.00 / g
  • 99%
  • Wuhan Qiami Technology Co., Ltd
2-Amino-N,N'-bis[hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide Actinomycin D, Actinomycin IV, Actinomycin C1, Dactinomycin Dactinomycin, DTM Actinomycin C1, Dactinomycin Actactinomycin A IV Cosmogen actinomycin7 actinomycinaiv actinomycindioicdacid,dilactone actinomycini(sub1) actinomycini1 actinomycinx1 acto-d chounghwamycinb dactinomycind dilactoneactinomycindacid dilactoneactinomycindioicdacid ediyl)))bis(n-methyl-l-valine)di-xi-lactone l-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-i)(1,4,7,10,13)o lyovaccosmegen meractinomycin nci-c04682 nci-co4682 nsc3053 oncostatink ACTINOMYCIN D FROM STREPTOMYCES SP. ACTINOMYCIN D 98% FROM STREPTOMYCES PARVULUS ACTINOMYCIN D CELL CULTURE 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo- 8-Amino-N-(2-amino-4,6-dimethyl-3-oxo-phenoxazin-1-yl)carbonyl-N'-[8-amino-4,6-dimethyl-7-oxo-9-[[3,6,10-trimethyl-7,14-bis(1-methylethyl)-2,5,8,12,15-pentaoxo-9-oxa-3,6,13,16-tetrazabicyclo[14.3.0]nonadec-11-yl]carbamoyl]phenoxazin-1-yl]carbonyl-4,6-dime Actinomycin D,93% Actinomycin DDactinomycin Actinomycin D(8CI,9CI) AD(VAN) Dactinomycin(USAN) 2-Amino-(N,N)-1-bis(hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1]-[1,4,7,10,13]oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide Actinomycin D,Actinomycin C1, ActinomycinIV, Dactinomycin Dactinomycin (50 mg) ACTINOMYCIN D extrapure for biochemistry Actinomycin C1, ActinomycinIV, Dactinomycin 1-ethanediyl)imino(2-(1-methylethyl)-carbonylimino(2-(1-hydroxyethyl)-1-oxo- 1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino)(1-oxo-2,1-ethan 3h-phenoxazine-1,9-dicarboxamide,2-amino-n,n’-bis(hexadecahydro-2,5,9-trimethy 6-dimethyl-3-oxo-xatetra-azacyclohexadecin-10-yl)- actd actinomycin-(thre-val-pro-sar-meval) actinomycin11cosmegen stereoisomerofn,n’-((2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-diyl)bis( Actinomycin C1 ACTINOMYCIN IV ACTINOMYCIN C, STREPTOMYCES CHRYSOMALLUS (-)-ACTINOMYCIN D ACTINOMYCIN D ACTINOMYCIN C ACTINOMYCIN C1 ACTINOMYCIN D FROM STREPTOMYCESSPECIES C ELL CULTUR ACTINOMYCIN D FROM STREPTOMYCES SPECIES ACTINOMYCIN D, FROM STREPTOMYCES SP., FO R FLUORESCENCE